TREM-1 Binding Proteins for Cardiovascular Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases such as atherosclerosis and myocardial infarction do not effectively address the inflammatory response mediated by Triggering Receptor Expressed on Myeloid cells 1 (TREM-1), which contributes to disease progression.
Innovation Solution
Development of antigen binding proteins specific for TREM-1, comprising specific light and heavy chain variable domain sequences that bind to TREM-1, thereby modulating its activity and reducing inflammatory cytokine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cardiovascular diseases are used, then existing therapeutic options are available, but the inflammatory response mediated by TREM-1 is not effectively addressed
Solution Approach 1:
The patent extracts and targets the specific harmful component (TREM-1) from the complex inflammatory response system. By developing antigen binding proteins that specifically bind to TREM-1, the invention isolates and neutralizes this particular mediator of inflammation without necessarily affecting other inflammatory pathways, thereby addressing the harmful inflammatory response while maintaining therapeutic reliability
Solution Approach 2:
The antigen binding proteins serve as intermediary molecules that block the interaction between TREM-1 and its ligands (such as PGLYRP1). This intermediary approach prevents the harmful inflammatory signaling cascade initiated by TREM-1 activation, effectively reducing the inflammatory response mediated by this receptor while allowing other physiological processes to continue
2Object-generated harmful factors
If TREM-1 activity is blocked to reduce inflammatory cytokines, then inflammatory response is reduced, but new therapeutic agents must be developed
Solution Approach 1:
The patent employs antibody technology, a well-established and replicated therapeutic approach, to create TREM-1 blocking agents. By using the proven antibody framework and applying it to target TREM-1 specifically, the invention leverages existing knowledge and development platforms rather than creating entirely new therapeutic modalities, thereby reducing the complexity of developing new therapeutic agents while effectively blocking TREM-1 activity and reducing inflammatory cytokine production
Data Source
AI summary
The present disclosure relates, in general, to methods of treating cardiovascular disease, such as atherosclerosis or myocardial infarction, using antigen binding proteins that bind to TREM-1, and compositions thereof.